The CURE trial demonstrated that clopidogrel on top of aspirin reduces the number of cardiovascular events (CV) compared to aspirin alone by 20% in patients with unstable angina or non-ST-elevated myocardial infarction compared to aspirin alone with an acceptable 1% increase of major bleedings. Based on this result, a long-term cost-effectiveness analysis was performed in Mexico. METHODS: An expert panel identified the resource used by patients suffering from a stroke or an acute MI, according to local practices. Costs were elicited from the IMSS health care institutions. The yearly costs included the acute and follow-up costs of events, including bleedings. Indirect costs were calculated using the time of work lost. The effectiveness measure was survival. The cost-effectiveness analysis used the societal perspective and incremental cost-effectiveness ratios (ICER) were calculated using a long-term Markov model. A 3% discount rate was applied for costs and outcomes. Sensitivity analysis was performed on the discount rate and the acute events' costs. RESULTS: The model yielded greater direct costs for the clopidogrel strategy ($12,155) vs. aspirin alone (US$11,821) and indirect costs were $164 versus $206 respectively. Total costs in the two arms were $12,319 for the clopidogrel strategy and $12,027 for aspirin alone. Treatment with the clopidogrel strategy resulted in a longer survival compared to aspirin (9.76 lifeyear gained (LYG) vs. 9.65LYG, respectively). Therefore, the incremental cost-effectiveness ratio of the clopidogrel strategy was $3350/LYG for direct costs and $2938/LYG for total costs. The sensitivity analysis indicated a maximum ICER of $6570/LYG using a 5% discount rate and the lowest cost reported per event. CONCLUSION: In this analysis, the cost per life year gained is lower the recommended threshold of acceptability defined by WHO (3xGDP per capita (US$30,177), indicating that Clopidogrel on top of aspirin is highly cost-effective in patients with UA/NSTEMI within the IMSS. University of Glasgow, Glasgow, Scotland, UK, 7 University of York, York, Heslington, UK OBJECTIVES: The Treating to New Targets (TNT) study, daily treatment with atorvastatin 80 mg (A80) reduced cardiovascular events by 22% compared with atorvastatin 10 mg (A10) in patients with coronary heart disease (CHD). The objective of this study was to evaluate the cost-effectiveness of this treatment strategy in Spain and Germany. METHODS: A lifetime model was developed to predict cardiovascular disease-related events (resuscitated cardiac arrest, hospitalized CHF, MI, stroke, revascularization, peripheral vascular disease, TIA, angina), costs, survival, and quality-adjusted life years (QALYs) for CHD patients receiving A80 versus A10 in the target countries. Treatment-specific event probabilities were estimated from the TNT trial and extrapolated to 10 years. Beyond year 10, equivalent cardiovascular risks were assumed for all patients. Post-event survival, event-specific utilities, and country-specific medical-care costs were estimated using published sources. All benefits and costs (€2005) were discounted 3.5% annually. RESULTS: In both settings, treatment with A80 is estimated to increase per-patient QALYs (8.39 vs. 8.25 in Spain, 8.19 vs. 8.05 in Germany), life years (10.99 vs. 10.86, 10.73 vs. 10.58), and costs of care (€11,468 vs. €7883, €12,546 vs. €10,237) compared with A10. Corresponding estimates of incremental cost-effectiveness of A80 versus A10 in each setting are €27,445 and €16,566 per QALY, and €26,912 and €15,809 per life year saved (LYS). In probabilistic sensitivity analysis, the likelihood that A80 is costeffective versus A10 (<€30,000/QALY or LYS) is 59.1% and 91.3% for QALY, and 60.3% and 88.0% for LYS, respectively. CONCLUSIONS: Intensive A80 treatment is estimated to be cost-effective versus A10 in secondary cardiovascular prevention in Spain and Germany. While prior studies have demonstrated the cost-effectiveness of moderate lipid-lowering therapy versus no treatment in this patient population, the results of our analysis suggest more intensive lipid lowering with atorvastatin also can be justified on cost-effectiveness grounds versus moderate statin therapy.
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COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND
The Treating to New Targets (TNT) study, daily treatment with atorvastatin 80 mg (A80) reduced cardiovascular events by 22% compared with atorvastatin 10 mg (A10) in patients with coronary heart disease (CHD). The objective of this study was to evaluate the cost-effectiveness of this treatment strategy in Spain and Germany. METHODS: A lifetime model was developed to predict cardiovascular disease-related events (resuscitated cardiac arrest, hospitalized CHF, MI, stroke, revascularization, peripheral vascular disease, TIA, angina), costs, survival, and quality-adjusted life years (QALYs) for CHD patients receiving A80 versus A10 in the target countries. Treatment-specific event probabilities were estimated from the TNT trial and extrapolated to 10 years. Beyond year 10, equivalent cardiovascular risks were assumed for all patients. Post-event survival, event-specific utilities, and country-specific medical-care costs were estimated using published sources. All benefits and costs (€2005) were discounted 3.5% annually. RESULTS: In both settings, treatment with A80 is estimated to increase per-patient QALYs (8.39 vs. 8.25 in Spain, 8.19 vs. 8.05 in Germany), life years (10.99 vs. 10.86, 10.73 vs. 10.58) , and costs of care (€11,468 vs. €7883, €12,546 vs. €10,237) compared with A10. Corresponding estimates of incremental cost-effectiveness of A80 versus A10 in each setting are €27,445 and €16,566 per QALY, and €26,912 and €15,809 per life year saved (LYS). In probabilistic sensitivity analysis, the likelihood that A80 is costeffective versus A10 (<€30,000/QALY or LYS) is 59.1% and 91.3% for QALY, and 60.3% and 88.0% for LYS, respectively. CONCLUSIONS: Intensive A80 treatment is estimated to be cost-effective versus A10 in secondary cardiovascular prevention in Spain and Germany. While prior studies have demonstrated the cost-effectiveness of moderate lipid-lowering therapy versus no treatment in this patient population, the results of our analysis suggest more intensive lipid lowering with atorvastatin also can be justified on cost-effectiveness grounds versus moderate statin therapy.
